The JN.1 strain of the virus should be combated by the COVID-19 vaccine’s next dosage, according to advice from the Food and Drug Administration.
Researchers have noted that JN.1, which was initially identified in the United States in September, is comparable to earlier strains but spreads more quickly and easily. The frequency of COVID cases attributed to JN.1 increased to 85% in January from 3.5% in November, according to the Centers for Disease Control and Prevention.
The best defense against illness, according to Texas A&M University biology professor Ben Neuman, is still getting vaccinated.
“It would be important, I would say, to get the updated vaccine as soon as it is available,” Neuman said. “It may not prevent infection completely, but it is, very much, the best hedge against dying of COVID.”
He added that the infection is still killing 500 people a week on average.
There are other circulating COVID strains known as KP.2 and KP.3, which are referred to as “FLiRT” variations. The FDA decided to focus on JN.1 since it is spreading more quickly, although they did contemplate having manufacturers formulate the new vaccine to target KP.2 and KP.3. Runny nose, sore throat, and fever are signs of FLiRT mutations. Because of the strains’ strong immunological resistance, breakthrough cases may be feasible, according to researchers.
Neuman said that some medical professionals think that because COVID is always evolving, a two-dose vaccination would offer the public greater protection.
“We have an immune system which is learning to recognize the virus and kills off all of the viruses it can recognize,” Neuman said. This causes the virus to alter, possibly a little more quickly than it would if our immune systems weren’t there. Thus, new COVID variations will continue to exist.”
Neuman stated that although the virus is continually evolving, you can still use outdated COVID tests in your medicine cabinet to identify strains that haven’t changed over time. However, he strongly advised utilizing updated tests.
